Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904659 | 0.98 | KIF11 (0.55) | KIF11 | |
| SCHEMBL5350718 | 0.98 | KIF11 (0.55) | KIF11 | |
| SCHEMBL21093254 | 0.98 | KIF11 (0.55) | KIF11 | |
| SCHEMBL17493269 | 0.94 | KIF11 (0.59) | KIF11 | |
| SCHEMBL4288415 | 0.85 | KIF11 (0.63) | KIF11 | |
| SCHEMBL18599373 | 0.80 | KIF11 (0.57) | KIF11 | |
| SCHEMBL25400195 | 0.80 | KIF11 (0.74) | KIF11 | |
| SCHEMBL5357811 | 0.78 | KIF11 (0.55) | KIF11 | |
| SCHEMBL8447104 | 0.78 | KIF11 (0.55) | KIF11 | |
| SCHEMBL22756327 | 0.78 | KIF11 (0.55) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021055-A1 | Asymmetric Piperazine-Based Cationic Lipids | TRANSLATE BIO, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025134071-A1 | MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS | SANOFI (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2023198857-A1 | \"GOOD\" BUFFER-BASED CATIONIC LIPIDS | SANOFI (FR) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023178167-A1 | ASYMMETRIC PIPERAZINE-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178167-A1 | ASYMMETRIC PIPERAZINE-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021055-A1 | Asymmetric Piperazine-Based Cationic Lipids | SGMS2, SPTLC2, SGMS1 | KIF11 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.